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ABSTRACT -- ~~ _
Since the first epidemiological evidence on the benefit
of lipid reduction in coronary heart disease (CHD) was
gathered, a number of questions have emerged in this
field of research. Consistent findings across a number
of landmark trials have shown that lipid-lowering ther-
apies significantly reduced major subsequent cardiovas-
cular events in coronary patients with high and moder-
ate low density lipoprotein (LDL) blood cholesterol
levels. Although there has been some confusion on the
effect of lipid intervention on mortality, recently defi-
nite answers have come from several major trials that
establish a clear decrease in coronary death for patients
Since the first epidemiological evidence on thebenefit of lipid reduction in coronary heart dis-
ease (CHD) was gathered, a number of questions
have emerged in this field of research. In this paper,
some of the most important questions regarding
lipid reduction and CHD are reviewed, and answers
to several of them are provided using examples from
landmark trials.
Secondary Prevention of Major
Cardiovascular Events
One of the first concerns of clinicians has been the
effectiveness of lowering elevated blood choles-
terol to prevent subsequent major cardiovascular
events in patients with proven CHD or who have
survived myocardial infarctions (MIs).
A number of trials have been conducted since the
1960s to assess the effect of lipid-lowering therapy
on this category of patient with high blood choles-
terol (Table 1). The first of these was the Coronary
Drug Project 111, which was the first large trial that
attempted to lower cholesterol in a meaningful way
in patients with MI. This study had several treat-
ment arms, but only the clofibrate and niacin treat-
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after reduction of plasma cholesterol levels. Primary
prevention in individuals with high LDL cholesterol lev-
els was shown to be beneficial in terms of cardiovascu-
lar event reduction; more data are needed to address
this issue for subjects with moderate LDL cholesterol
levels. Reduction of LDL cholesterol below normal lev-
els appeared to be beneficial for coronary patients, but
again, further research is needed to elucidate this point.
To date, major trials have answered some of the many
questions pertaining to lipid-lowering therapies; further
research will continue to provide information and allow
patients to benefit maximally from lipid interventions.
---_._---- --_._---_._-
ment arms were completed without adverse effects
causing their discontinuation. .More recently, in
Stockholm, another study investigated the effect of
simultaneous treatment with clofibrate and niacin
in post-MI patients, as well as the effect of an ileal
bypass procedure that causes the gut to lose more
cholesterol and bile acids than usual and lowers
cholesterol intake. In this series of studies, which
was conducted between 1965 and 1990 and con-
sidered patients with high blood cholesterol, the
reduction in cholesterol level ranged from 6-23 %
with a 9-35% reduction in myocardial infarction
plus coronary death [11.
In the 1980s, several clinical trials examined the
effect of statins, a new and more effective therapy
to lower LDL cholesterol than any of the treat-
ments previously studied. The most definitive an-
swer on prevention of subsequent CHD in patients
with high blood cholesterol came from the Scandi-
navian Simvastatin Survival Study Group (4S) with
4444 individuals who had proven coronary artery
disease 12]. This landmark trial showed that a treat-
ment with sirnvastarin over 5-and-one-half years re-
sulted in a 34% reduction in coronary death and
myocardial infarction. Hence, the 4S study demon-
strated that lowering blood cholesterol levels could
prevent myocardial infarction and coronary disease
death. In addition, a consistent 32% reduction in
revascularization procedures (mainly bypass sur-
gery) was observed. Furthermore, the number of
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Table I Landmark lipid intervention trials in secondary
prevention
4S. Scandinavian Sirnvastatin Survival Study; CARE. Cholesterol and Recurrent
Events study; LDL. low density lipoprotein; POSCH. Program on the Surgical
Control of Hypercholesterolemia.
hospital days from all cardiovascular disease, in-
cluding procedures, treatment of myocardial in-
farction, stroke, and heart failure, was 34% lower
in the treated population compared to the placebo
controlled group. The value of reducing high
blood cholesterol was clearly established.
A more difficult question remained concerning
whether lowering cholesterol therapy would be ben-
eficial to post-MI patients without high LDL choles-
terol, that is, below 160 mgldL (according to the
National Cholesterol Education Program (NCEP)
guidelines 13]). The Lipid Research Clinic Commu-
nity Study [4], which included 10 communities
across the United States and Canada, showed the in-
cidence of cardiovascular deaths in subjects with
CHD and LDL cholesterol levels below 160 mg/dL
to be five times higher than in subjects without
CHD. Therefore, clinically evident coronary disease
remains the major predictor of future CHD. Coro-
nary patients with LDL cholesterol below 130 mgl
dL, the desirable range for the noncoronary patient,
had a considerably lower incidence of CHD. It is
therefore more difficult to demonstrate benefit
when reducing LDL cholesterol from around 130
mg/dl, than from 160 mg/dL.
The Cholesterol and Recurrent Events (CARE)
[5] study was a randomized, placebo-controlled,
double-blind trial evaluating the effect of pravasta-
tin on coronary patients. Enrolled in this trial was a
population of 4200 men and women with an aver-
age age of 59, ranging between 21 and 75 years.
Baseline cholesterol was 209 mg/dL, and LDL cho-
lesterol ranged from 115 to 174 mg/dL (mean 139
mg/dL). After 5 years a 28% reduction in LDL cho-
lesterol and a slight rise (5%) in high density lipo-
protein (HDL) cholesterol were observed for
treated patients, with a statistically significant 24%
reduction of MI or CHD death. Reductions in coro-
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nary death and all-cause mortality were not statis-
tically significant. Besides pravastatin, patients
were also receiving other treatments for their condi-
tion, including aspirin (83%), beta-blockers (40%),
calcium antagonists (40%), nitrates for angina
(33%), and angiotensin-converting enzyme inhibi-
tors (J 5%). When compared with patients in the 4S
study, reduction in cardiovascular events was less.
The reduction for patients in the 4S study with high
cholesterol levels demonstrates that the benefit of
lipid-lowering therapy is less dramatic but still im-
pressive for patients with average cholesterol levels.
This issue will be further investigated in the
Lipid Trial [6]. This large study, similar to the
CARE study, was conducted over 7 years in Aus-
tralia and New Zealand and involved 7500 men
and 1500 women with average blood cholesterol
values (155-270 mg/dL). Results of this trial should
be published shortly. They will add a considerable
body of data on the elderly and diabetics.
Correlation between Clinical Events
and Lesions
'Theoretically, reduction in clinical events implies a
decrease in the disease progression rate and in the
atherosclerotic lesion itself. A number of trials in-
volving angiographic or other types of anatomical
assessment have been performed to investigate the
progression rate of stenosis of arteries, the remis-
sion of existing lesions, and the prevention of new
lesions. Although statistical significance was not
achieved in some studies, a consistent and system-
atically higher progression of the disease was ob-
served for patients in the control groups compared
to those receiving several different treatments.
These studies evaluated the effect of a variety of
therapies, including diet, resin therapy, niacin,
lovastatin, surgery, and, in some cases, combina-
tions of several therapies. The common goal of the
trials was to modify lipoprotein levels, and it ap-
peared that a consistent reduction in disease pro-
gression occurred without respect to the choles-
terol reduction mechanisms involved. The most
impressive change was the consistent event rate re-
duction, primarily myocardial infarction and cor-
onary disease death observed in these trials.
Mortality and Lipid-Lowering Therapies
Another key question concerns the effect of reduc-
ing elevated blood cholesterol on total mortality in
patients with known vascular disease. There has
been some confusion on this issue, mainly because
112
early trials that were not designed to show reduc-
tion in mortality failed to do so. During the Lipid
Research Clinic Trial [71, about 2000 patients were
enrolled in the treatment arm in which four patients
committed suicide, six individuals died accidentally,
and one was shot. In the placebo group, however,
only two patients committed suicide and only two
died accidentally in the placebo group. Three years
later, the Helsinki Heart Study [8] reported four
suicides in the lowering cholesterol treatment group
compared to only one in the placebo group. Four
accidents were also reported for each group, but
only one individual in the treatment group was shot.
Based on those results and a suspicion of a relation-
ship between trauma and lowering cholesterol ther-
apy, a whole series of studies was initiated. Some
compared the aggression of monkeys eating low-fat
diets to those with high animal fat diets. Millions of
dollars might have been spent to elucidate the ques-
tion of trauma in lower cholesterol groups when re-
sults of the 4S [2] trial were released. The 4S trial
was designed to investigate whether lowering blood
cholesterol could reduce total mortality. A 42 % re-
duction in coronary death was reported, resulting
in a 30% reduction in all deaths. There were three
additional cases of trauma in the placebo group
and one case in the simvasratin-treated group. The
results of many studies with statins have now been
completed with no difference in death by trauma
between placebo and treatment groups.
In the World Health Organization Study [9], a
slight increase in total mortality was reported for ev-
ery category of death, and overall was significantly
higher in the clofibrate treatment group compared
to the placebo group. However, this study presented
a series of problems, including enumeration of the
endpoints, and has been considered untrustworthy
on this point. An answer to this issue of low choles-
terol as a cause of death came from epidemiological
studies. The Framingham Heart Study 1101 re-
ported a rank order reduction in total mortality
with lower cholesterol. Patients with the highest
cholesterol died earliest. Similarly, a follow-up
over 40 years of Johns' Hopkins medical students
showed that individuals in the lowest 10th percen-
tile of cholesterol lived the longest, whereas those
in the highest 10th percentile lived the shortest
time. A rank order relationship between baseline
cholesterol value and mortality was observed [11].
Time Response to Lipid-Lowering Therapy
An important issue, especially when calculating
cost-benefit ratios, concerns the time it takes before
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the clinical benefit of a cholesterol-lowering ther-
apy is statistically significant. In the CARE study
[5],2 years of treatment were necessary to show a
clinical impact of the lipid-lowering treatment. In
the West of Scotland Coronary Prevention Study
(WOSCOPS) [12], a clear benefit in any of the cor-
onary disease manifestations was observed around
13 or 14 months at the earliest. When examining
a large series of clinical trials, the difference in the
event rate between treatment group and placebo
group is usually evident after 1 to 2 years of ther-
apy, independent of the type of event. Hence, the
first 12 months of lipid-lowering therapy are nec-
essary to see the benefit of the treatment in the fol-
lowing 12 months, an effect that occurred much
quicker than expected.
Primary Prevention
Another crucial question pertains to primary pre-
vention: Will reducing high blood cholesterol in in-
dividuals without clinically evident vascular disease
decrease the incidence of myocardial infarction and
coronary death and prevent that first episode from
occurring? A series of studies have attempted to an-
swer this question using a variety of interventions
including diet, fibrares (gemfibrozil, clofibrate), res-
ins, and, more recently, statins (Table 2).
The Oslo Study [1], an early trial before statins
were available, was a diet and smoking cessation
study. Most of the treatment impact on reducing
cardiovascular events came from diet and lower
cholesterol since, by the end of the trial, there
were equal numbers of smokers in the two groups.





Subjects with high lDl
cholesterol
Oslo Study [I] diet + smoking <47
cessation
World Health Organization clofibrate <20
Study [I]
Upjohn [I] colestipol <23
lipid Research Clinics cholestyramine < 19
Coronary Primary
Prevention Trial [I]
Helsinki Heart Study [I] gemfibrosil < 34
WOSCOPS [12] pravastatin < 31
Subjects with moderate LDl
cholesterol
AFCAPSfTexCAPS [13] lovastatin ongoing
AFCAPSITexCAPS, Air ForcelTexas Coronary Atherosclerosis Prevention
Study; LDL, low density lipoprotein; WOSCOPS, West of Scotland Coronary
Prevention Study.
Landmark Trials in Lipid Reduction
For the World Health Organization Study [91, al-
though an increase in total mortality was observed
in the treated group, the actual MY and CHD
death rate was reduced with clofibrate. Two large
clinical trials showed almost identical results: one
conducted in private practice and treating with
colestipol, and another more scientifically rigor-
ous trial treating with cholestyramine [1]. The
Helsinki Heart Study [81 investigated the effect of
gemfibrozil and included a large number of indi-
viduals with high triglycerides and low HDL. The
observed benefit could be attributed not only to
lowering LDL cholesterol but also to a rise in HDL
cholesterol. This drug lowered triglycerides dramat-
ically, but the event reduction appeared to be ex-
plained by HDL and LDL changes. All of these tri-
als were conducted over many years with several
thousand individuals and resulted on average in a
10% reduction in total cholesterol and a 20-25%
reduction in coronary heart disease events. Interest-
ingly, the most dramatic reduction was reported for
diet and smoking cessation (Oslo trial [1 J).
The first primary prevention study to use a sta-
tin (pravastatin) was the WOSCOPS [12] trial,
which investigated the effect of cholesterol reduc-
tion in a high-cholesterol population. It was con-
ducted in Scotland where CHD rates are among
the highest in the world. A large group (6600) of
men with ages between 45 and 64 years and with
cholesterol levels above 250 mgldL were randomly
assigned to treatment with pravastatin or placebo
and were followed in a blinded fashion for 5
years. Lipid-lowering treatment resulted in a 26%
reduction in LDL cholesterol (close to that of the
CARE study), a 5% reduction in HDL cholesterol,
and a 31 % reduction in the primary endpoint (ie,
myocardial infarction plus coronary heart disease
death). Endpoints were only counted once in any
given individual. Coronary death was reduced by
33% and all-cause mortality was reduced by 22%.
Both the early and the more recent studies clearly
showed that cardiovascular events could be pre-
vented by lipid-lowering therapy in noncoronary
patients with high blood cholesterol. However, the
question remains: Can subjects with lower levels of
blood cholesterol benefit from these therapies?
The Air Force/Texas Coronary Atherosclerosis
Prevention Study (AFCAPS/TexCAPS) [13] was
designed to investigate whether individuals with
low to moderate LDL cholesterol and low HDL
cholesterol levels benefit from treatment with lov-
astatin, This randomized double-blind trial was
conducted in Texas and involved a military (US Air
Force) population and a civilian population (total-
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ing 6600) including women and a large number of
diabetics and elderly persons. Lovastatin doses
were increased up to 40 mgld attempting to achieve
an LOL cholesterol level lower than 110 mgldL.
The development of unstable angina, fatal MY, non-
fatal MI, or sudden coronary death was counted as
endpoints. The results of this trial will be reported
shortly and will make available a much larger data-
base on this issue of primary prevention.
Reducing Cholesterol below Normal Levels
Current guidelines recommend reducing LDL cho-
lesterol to "100 mgldL for coronary patients. A
cholesterol level of 130 mg/dL is considered nor-
mal. These guidelines have been criticized mainly
because of the lack of data on this specific issue.
Recently, the Post Coronary Artery Bypass Graft
Trial (post-CABG) study [141 attempted to answer
this question in a very specific setting. Patients
who had a coronary artery bypass grafting proce-
dure 1 to 11 years prior to the trial were randomly
assigned to a treatment regimen combining diet,
lovastatin, and cholestyrarnine, as necessary, to
achieve the LDL goal. The study design used a
random assignment for treatment towards two
goals: 1) a moderate goal of reducing LDL choles-
terollevel to 130-140 mg/dL; or 2) a more aggres-
sive goal of reducing LDL cholesterol below 85
mgldL. An angiogram was performed at baseline
to define the anatomy of grafts and native vessels.
The moderate goal was achieved in 6 months, and
a mean level of 132-134 mg/dL was maintained
over the remainder of the 36-month period. The
goal of the more aggressive treatment was not
achieved; however, mean LDL cholesterol of 93-
96 mgldL was maintained over the 12-36-month
period.· Angiography was conducted after 3 years
and showed fewer lesions and a significant reduc-
tion in the narrowing of vein grafts in the treated
group compared to the placebo group. In terms of
new procedures, which is a critical point for both
clinician and patient, 29% fewer angioplasties or
bypass grafts were performed in the aggressively
treated group compared to the moderately treated
group in the 24th through 48th month of moni-
toring. In that very specific set of patients, it ap-
peared that aggressive LDL cholesterol reduction
was beneficial for grafts, but the impact on lesions
in native vessels remains to be defined.
Similarly, can a lipid-lowering therapy prevent
a lesion from resulting in a clinical event? The
Atorvastatin Versus Revascularizarion Treatments
(AVERT) study [15], which should be completed
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in July 1998, is investigating whether LOL choles-
terol reduction will result in fewer major clinical
endpoints than angioplasty with usual care. Pa-
tients (320) with a target lesion defined as having
at least 50% stenosis in one artery and considered
not to be in need of an immediate angioplasty
were randomly assigned to receive 80 mg atorvas-
tatin or to undergo angioplasty in the defined
stenotic lesion. At baseline, LOL cholesterol levels
were above 130 mg/dL with triglycerides under
400 mg/dL. Reduction in event rate, including
coronary death, cardiac arrest, MIs, cerebrovascu-
lar accident, need for another bypass graft, angio-
plasty, or unstable angina, are being followed over
18 months. Change in angina class and cost analy-
sis will also be tackled in this study, which will
provide new data on this issue.
With new drugs and with combination therapy,
LOL cholesterol levels can be reduced to well under
130 mg/dL. Whether more aggressive reduction is
beneficial, and for which group of individuals, re-
mains to be determined. Subanalyses of data from
previous trials are underway to provide some infor-
mation. However, those analyses in retrospect are
more hypothesis-generating than question-answering.
New data are required to provide dues on aggressive
reduction of LOL cholesterol levels that might result
in future modification of the current guidelines.
Conclusions
Since the first hypothesis about the effect of lipid-
lowering therapy on CHO was presented, consider-
able data has been accumulated. Many questions
have been answered, allowing provision of guide-
lines on lipid intervention. The largest number of
people will benefit from these treatments if cost re-
duction can be demonstrated; this wiII require new
ways of lowering costs. This wonderful story of pre-
ventive medicine was initiated by epidemiologists al-
most 25 years ago, and through clinical trials it has
now been placed in the economists' hands, who
hopefully will transform and extend it to the future.
This article was prepared with the assistance of BioMed-
Com Consultants inc., Montreal, Canada.
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